Floatz logo

Evomela

CD20-Positive Neoplastic Cells Present

Fred Hutchinson Cancer CenterPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

48 Active assets in the CD20-Positive Neoplastic Cells Present cohort.

Asset / SponsorPhaseRating
Zanubrutinib
Curis, Inc.
Phase 2BB
Cyclophosphamide
University Hospital, Basel, Switzerland
Phase 2BB
PREDNISONE TABLETS
Curis, Inc.
Phase 2BB
Inno-206
Curis, Inc.
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Curis, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →